All rights reserved. No reuse allowed without permission.

### 1 Title

2

### 3 Rapid surveillance platforms for key SARS-CoV-2 mutations in

#### 4 Denmark

5

#### 6 Authors

- 7 Katja Spiess<sup>1,5#</sup>, Vithiagaran Gunalan<sup>1,5</sup>, Ellinor Marving<sup>1</sup>, Sofie Holdflod Nielsen<sup>2</sup>,
- 8 Michelle G. P. Jørgensen<sup>2</sup>, Anna S. Fomsgaard<sup>1</sup>, Line Nielsen<sup>2</sup>, Alonzo Alfaro-
- 9 Núñez<sup>1</sup>, Søren M. Karst<sup>1</sup>, The Danish COVID-19 Genome Consortium (DCGC)<sup>4</sup>,
- 10 Shila Mortensen<sup>1</sup>, Morten Rasmussen<sup>1</sup>, Ria Lassaunière<sup>1</sup>, Maiken Worsøe
- 11 Rosenstierne<sup>3</sup>, Charlotta Polacek<sup>1</sup>, Jannik Fonager<sup>1</sup>, Arieh S. Cohen<sup>2</sup>, Claus Nielsen<sup>1</sup>,
- 12 Anders Fomsgaard<sup>1</sup>

# 1314 Affiliation

- <sup>1</sup>Department of Virus and Microbiological Special Diagnostics, Statens Serum
- 16 Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
- <sup>2</sup> Test Center Danmark, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S,
- 18 Denmark
- <sup>3</sup> Qlife Aps. Symbion, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark
- 20 <sup>4</sup> <u>https://www.covid19genomics.dk/about</u>
- <sup>5</sup> These authors contributed equally
- 22 <sup>#</sup>Corresponding author: Katja Spiess, <u>ktsp@ssi.dk</u>
- 23

### 24

### 25 Abstract

- 26
- 27 Multiple mutations in SARS-CoV-2 variants of concern (VOCs) may increase,
- 28 transmission, disease severity, immune evasion and facilitate zoonotic or
- anthoprozoonotic infections. Four such mutations,  $\Delta$ H69/V70, L452R, E484K and
- 30 N501Y, occur in the SARS-CoV-2 spike glycoprotein in combinations that allow
- 31 detection of the most important VOCs. Here we present two flexible RT-qPCR
- 32 platforms for small- and large-scale screening to detect these mutations, and schemes
- 33 for adapting the platforms for future mutations. The large-scale RT-qPCR platform,
- 34 was validated by pair-wise matching of RT-qPCR results with WGS consensus
- 35 genomes, showing high specificity and sensitivity. Detection of mutations using this
- 36 platform served as an important interventive measure for the Danish public health
- 37 system to delay the emergence of VOCs and to gain time for vaccine administration.
- 38 Both platforms are valuable tools for WGS-lean laboratories, as well for
- 39 complementing WGS to support rapid control of local transmission chains worldwide.
- 40
- 41

### 42 Keywords

- 43 Pandemic, SARS-CoV-2, key mutations, variant of concern, variant of interest, RT-
- 44 qPCR, large scale screening, whole genome sequencing, national surveillance
- 45 program
- 46 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

All rights reserved. No reuse allowed without permission.

#### 47 48 Introduction

#### 49

50 The global SARS-CoV-2 pandemic, which raised with the identification of this novel 51 coronavirus in late 2019, has seen the emergence of several variants, each with a 52 distinct set of mutations<sup>1</sup>. Early detection of new SARS-CoV-2 mutations and 53 associated measures to decrease the risk of spread are important to control local 54 outbreaks of SARS-CoV-2 variants, especially those which have been designated Variants of Concern (VOCs)<sup>2,3</sup>. The latter are defined by increased transmissibility, 55 severity of infections and resistance to immunity<sup>4–8</sup>. VOCs include the Alpha 56 57 (B.1.1.7) and (B.1.1.7 + E484K), Beta (B.1.351), Gamma (P1) and Delta (B.1.617.2)

58 variants (Fig.1A-C/Tab. 1).

59 60

,	Table Toverview of SARS-Cov-2 variants, occurrence and evidence of impact						
	Variant	Variant	First Observed/	Impact on	Impact		

Variant of concern	Variant	First Observed/ Country	Impact on Transmissibility	Impact on Severity	Impact on Immuni ty
Alpha*	B.1.117	September 2020/ United Kingdom	Yes <sup>5</sup>	Yes <sup>8</sup>	No
Beta	B.1.351	September 2020/South Africa	Yes <sup>9</sup>	Yes <sup>8,10</sup>	Yes 9,11
Gamma	P.1	December 2020/ Brazil	Yes <sup>12</sup>	Yes <sup>8</sup>	Yes <sup>7</sup>
Delta	B.1.617.2	December 2020/India	Yes <sup>13</sup>	Yes 6,13,14	Yes 6,14,15

62

61 \* former variant of concern, now classified as de-escalated variant/ adapted from<sup>5</sup>

63

64 In all these VOCs, combinations of key mutations are present in S: N501Y in the 65 variants Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1); E484K in the variants

Beta (B.1.351) and Gamma (P.1) and within the emerging Alpha B.1.1.7 variant<sup>16</sup>; 66

L452R in the Delta (B.1.617.2) variant and  $\Delta$ H69/V70 in the variants Alpha (B.1.1.7) 67

68 and B.1.1.298.

The N501Y mutation occurs in the receptor-binding interface and confers a 69

70 substantial increase in the binding affinity of the S for the human angiotensin-

converting enzyme 2 (hACE2) protein<sup>17</sup>. HACE2 interaction with the S is essential for 71

virus entry and infection of the cells<sup>18</sup>. The E484K mutation has been identified as an 72

immunodominant spike protein residue, facilitating escape from several monoclonal 73

antibodies, as well as antibodies in convalescent plasma<sup>19-21</sup>. Altered immune 74

recognition has also been described for the L452R mutation $^{21-23}$ . The key mutation 75

76  $\Delta$ H69/V70, a two amino acid deletion, has appeared in multiple SARS-CoV-2

77 variants at different geographical locations across Europe. In Denmark,  $\Delta$ H69/V70

was detected in local outbreaks in mink farms in Northern Jutland <sup>24,25</sup>. The spread of 78

79 this deletion in combination with additional mutations (notably Y453F) resulted in the SARS-CoV-2 mink variants B.1.1.298, which transmitted both ways between humans

80 and mink; also giving rise to the early "cluster 5" variant  $^{24,26}$ . 81

82

83 The identification of these variants and the mutations that form their signature are

84 largely dependent on Whole Genome Sequencing (WGS) of SARS-CoV-2 from

85 infected individuals. In addition, WGS of SARS-CoV-2 also elucidates sets of novel

86 mutations potentially linked to changes in viral properties or associated with vaccine

- 87 breakthrough. However, the utility of WGS in a pandemic such as this also carries
- 88 with it a significant cost in the form of reagents, equipment as well as turnaround time

All rights reserved. No reuse allowed without permission.

89 - the average time from sample to genome being  $\sim$ 1-7 days depending on the scale of 90 sequencing performed. This has led to the development of alternatives to WGS such 91 as SARSeq, which is based on sequencing of the ectodomain of the SARS-CoV-2 spike protein<sup>27</sup> or sequencing of the whole S gene using Sanger sequencing<sup>28</sup>. 92 93 While such approaches yield cost and reagent savings, the turnaround time, 94 preparation effort for these and cost are still higher compared to RT-qPCR detection 95 platforms. In addition, qPCR technology is inarguably one of the cornerstones of 96 modern infectious disease diagnostics, thus expertise and equipment is readily 97 available and is not hindered by technical issues that might present themselves with 98 newer technologies, which could potentially delay the implementation of such 99 screening approaches. In order to detect SARS-CoV-2 mutations in near real-time 100 after sample acquisition and to allow for implementation at different scales (both 101 small and large), we developed fast, robust and flexible RT-qPCRs platforms using 102 state-of-the-art modified detection probes. Small-scale screening entails the 103 simultaneous detection of three key mutations in a multiplexed RT-qPCR, where sets 104 of variant-specific mutations can be replaced by a single signature mutation of 105 concern such as for the Delta (B.1.617.2) variant with the L452R mutation. The large-106 scale screening strategy entails the detection of four key mutations by a combination 107 of multiplexed and single RT-qPCRs running in parallel in a 384-well format. 108 Validation of the large-scale implementation of this RT-qPCR platform was 109 performed for 9572 positive samples collected between 6<sup>th</sup> June 2021 and 11<sup>th</sup> July 110 2021 as part of the national surveillance program in Denmark using paired WGS 111 consensus genomes derived from SARS-CoV-2 positive samples. From here, the 112 specificity, sensitivity, Positive Predictive Value (PPV) and Negative Predictive 113 Value (NPV) were determined for the large-scale RT-qPCR platform. The RT-qPCR 114 platforms for both small- and large-scale screening are designed as flexible detection 115 systems, where new mutations of concern can be included, thereby following the 116 course of the pandemic with minimal lag time.

- 117 118
- 119 **RESULTS**
- 120
- 121 122

### SMALL SCALE SCREENING OF SARS-COV-2 VARIANTS OF CONCERN

For laboratories with small amounts of positive SARS-CoV-2 samples or without the capacity to screen on a large scale for SARS-CoV-2 variants we developed a multiplexed RT-qPCR (v.1) that can detect three key mutations ( $\Delta$ H69/V70, E484K and N501Y) simultaneously (**Fig. 2A**). As proof of concept to determine if a key mutation can be replaced by another, we replaced the  $\Delta$ H69/V70 with the L452R mutation present in the delta variant (B.1.617.2) in the multiplex RT-qPCR (v.2) (**Fig. 2B**).

130

### 131 Multiplexed RT-qPCR v.1

132

133 As a first step in the multiplexed RT-qPCR v.1 we developed a primer/probe pair 134 detecting the  $\Delta$ H69/V70 and WT sequence, respectively (**Fig. 2C-D**). The limit of

detecting the  $\Delta H69/V70$  RT-qPCR was 5 copies/µl for the  $\Delta H69/V70$  performing a

dilution serious with a PCR standard TWIST control (Alpha B.1.1.7) (**Fig. 3E/ Suppl.** 

- Tab.2). PCR-positive SARS-CoV-2 patient samples with paired consensus genomes
- from WGS were included into the  $\Delta$ H69/V70 RT-qPCR. The  $\Delta$ H69/V70 or WT

All rights reserved. No reuse allowed without permission.

139 nucleotide sequence was detected independent of the concentration of the SARS-140 CoV-2 sample (amount of SARS-CoV-2 RNA included per sample into the PCR) 141 (Fig. 2F) and could be detected in samples of the Alpha B.1.1.7, B.1.258 and 142 B.1.1.298 variants, where this key mutation is present (Suppl. Fig. 1A-C). The  $\Delta$ H69/V70 RT-qPCR correctly detected the  $\Delta$ H69/V70 in SARS-CoV-2 positive 143 144 samples and did not amplify samples positive for respiratory tract viruses other than 145 SARS-CoV-2 (10/10 samples) (Suppl. Tab. 3). After successful validation, this RT-146 qPCR was incorporated as a part of the national surveillance program in Denmark 147 driven by TestCenter Denmark, as a large-scale screen for SARS-CoV-2 variants 148 harbouring  $\Delta$ H69/V70 (starting on December 18, 2021). By mid-February 2021 the 149 Alpha B.1.1.7 variant was the most prominent variant in Denmark (Fig. 2G) and at 150 the end of March, about 80% of all SARS-CoV-2 patient samples were tested positive 151 for the  $\Delta$ H69/V70 deletion (Fig. 2I), which was confirmed by WGS (Fig. 2H, Suppl. 152 Fig. 1D). Therefore, it was investigated if the  $\Delta$ H69/V70 RT-qPCR could be 153 multiplexed, which would then allow for the incorporation of further mutations 154 present in other Variants of Concern. While the Alpha (B.1.1.7) variant was the most 155 dominant variant in that time period, Beta (B.1.351) and Gamma (P.1) were still 156 circulating in Denmark (Suppl. Fig 1 D). As a first step, the  $\Delta$ H69/V70 RT-qPCR ran 157 together with the diagnostic SARS-CoV-2 E-Sarbeco PCR (E-gene)<sup>29</sup>. The sensitivity 158 of the  $\Delta$ H69/V70 RT-qPCR was found not to be reduced when multiplexed with the 159 E-Sarbeco RT-qPCR (Suppl. Fig. 1E). In conclusion, the  $\Delta$ H69/V70 RT-qPCR was 160 determined to be sensitive and specific for the detection of the  $\Delta$ H69/70 as well as 161 insensitive to multiplexing. To detect further key-mutations present in SARS-VOCs 162 (Alpha/Beta/Gamma/Delta) and other variants of interest, we developed primers and 163 probes to detect the L452R, E484K and N501Y mutations. Compared to the 164  $\Delta$ H69/V70 deletion where the probe targets a stretch of a deletion of six nucleotides. 165 the probes for the three key mutations listed above differ only by one nucleotide substitution within the S. Therefore, we increased their binding affinity to the 166 167 mutations or the WT sequence by modifying the probes as black whole quencher plus- (BHOplus), locked nucleic acid- (LNA) or minor grove binding (MGB) 168 169 conjugated probes. For the different RT-qPCRs, we tested for each mutations all 170 primer and probe combinations, with all three probe modifications. For the N501Y 171 mutation e.g., the MGB-conjugated probes for the N501Y mutation in the RT-qPCR 172 were observed to be superior to locked nucleic acid (LNA) - conjugated probes, where 173 a specific signal was detected for either the mutation or WT sequence. In contrast, the 174 LNA probes in the N501Y RT-qPCR detected the right mutations present in the 175 variants, but additional allelic discrimination analysis was needed to discriminate 176 between the intensity of the signal for the mutation or the WT probe at a Ct of 45 177 (Suppl. Fig. 2A-D). 178 For the L452R mutation, BHQ plus conjugated probes were found to be absolutely 179 specific compared to the LNA- and MGB conjugated probes (Fig. 3A-B). The limit of 180 detection for L452R was determined by a dilution series of a patient sample with 181 known sequence information for the delta variant (B.1.617.2) and tested in parallel in

the L452R RT-qPCR and the E-Sarbeco RT-qPCR (Fig. 3C). The L452R RT-qPCR
was about 2-fold less sensitive than the E-Sarbeco RT-qPCR (Fig. 3C).

- 184 The best results for the E484K mutation were gained using MGB conjugated probes
- 185 that were refined to generate a signal specific to mutation or WT nucleotide,
- 186 respectively (**Fig. 3D-E, G-H**). The limit of detection for the E484K RT PCR was
- 187 found to be 52 and 5 copies/µl respectively, performing a dilution series with the
- 188 TWIST control Beta B.1.351 and Gamma P.1 (Fig. 3F, I, Suppl. Tab.1).

All rights reserved. No reuse allowed without permission.

#### 189

190 As a signal detected was specific either for the key mutations or the WT sequence, it 191 was possible to only include the probes detecting the key mutations (L452R, E484K 192 and N501Y) or the  $\Delta$ H69/V70 into the multiplexed RT-qPCRs v.1 and v.2 (Fig. 3J-193 **O**). The probe for the  $\Delta$ H69/70 was further modified as a Zen-conjugated probe in the 194 multiplexed RT-qPCR v.1 to increase the signal intensity for this probe competing 195 with the MGB-conjugating probes for E484K and N501Y mutations. Testing SARS-196 CoV-2 positive patient samples with known whole genome sequence information in 197 the multiplexed RT-qPCR (v.1), the key mutations  $\Delta$ H69/V70, E484K and N501Y 198 present in the Alpha (B.1.17), Beta (B.1.351), B.1.5125 and P.2 were detected 199 simultaneously if present in all patient samples (23/23) (Fig. 3J-L) (Suppl. Tab 4). 200 The limit of detection for the different mutations was moderately reduced to around 201 50 copies/µl for the different mutations in the multiplexed RT-qPCR v.1 (Suppl. 202 Tab.6). To determine the specificity of the RT-qPCR v.1 we tested samples 203 containing respiratory tract viruses other than SARS-CoV-2. Five positive signals 204 could be detected for samples of respiratory tract viruses, but with a CT higher than 205 38 in the multiplexed **RT-qPCR v.1** (Suppl. Tab. 5). Repeating the experiments 206 twice with the same samples in **RT-qPCR v.1** resulted in a negative result (**Suppl.** 207 Tab.5). As the limit of detection for the multiplex RT-qPCR v.1 was at a CT of 37 208 for the N501Y mutation, positive Ct values > 38 should be considered as negative 209 (Suppl. Tab. 6).

210

212

#### 211 Multiplexed RT-qPCR v.2

213 As proof of concept and to investigate the robustness of the multiplexed RT-PCR we 214 investigated if the  $\Delta$ H69/V70 could be replaced by the L452R mutation, present in the 215 delta variant (B.1.617.2) in the multiplexed RT-qPCR v.2. As it is recommended to 216 limit the number of MGB-conjugated probes in a multiplex RT-qPCR, we combined 217 the two MGB-conjugated probes for the E484K and N501Y mutations with a BHQ-218 plus-conjugated probe for the L452R mutation. With this approach the three key 219 mutations L452R, E484K and N501Y could be simultaneously detected in 31/31 220 samples with known sequence information for the alpha (B.1.1.7), beta (B.1.351) and 221 zeta (P.2) variants in the multiplexed RT-qPCR v.2 (Suppl. Tab.3).

222

223 The multiplexed small-scale RT-qPCR platform offers a flexible and fast detection 224 system to rapidly identify key mutations present in SARS-CoV-2 VOCs and 225 mutations of interest. Notably, new key mutations can be accommodated by 226 exchanging one of the existing sets. This forms the basis of a flexible detection 227 platform where three key mutations can be detected in parallel in the multiplexed RT-228 qPCRs for small-scale screening.

- 229
- 230
- 231 232

### LARGE SCALE SCREENING OF THE VARIANT RT-qPCR AS PART OF THE NATIONAL SURVEILLANCE PROGRAM IN DENMARK

233

234 The same primer and probes designed for the four key mutations ( $\Delta$ H69/V70, L452R, 235 E484K and N501Y) included into the multiplexed RT-qPCR for small-scale screening 236 were further validated for large-scale screening, implemented to support the national

237 surveillance program in Denmark in addition to WGS, supporting the public health

238 system to delay the emergence of VOC. Large-scale screening consisted of RT-

All rights reserved. No reuse allowed without permission.

239 qPCRs running in parallel on a 384-well plate allowing for parallel detection of the 240 four key mutations. The two key mutations,  $\Delta$ H69/V70 and N501Y run as 241 multiplexed RT-qPCR in large scale, were detected in 17/17 (100 %) of patient 242 samples with known sequence for the Alpha (B.1.1.7) and Beta (B.1.351) variants 243 (Suppl. Tab. 7). The L452R and E484K mutations were correctly detected in single 244 RT-qPCR reactions in 18/18 (100%) and 31/31 (100%) patient samples respectively, 245 with known sequence information for the Alpha (B.1.1.7), Beta (B.1.351), Delta 246 (B.1.617.2), Zeta (P.2) or B.1.525 variants (Suppl. Tab. 8-9). The 247 ΔH69/V70/N501Y, L452R and E484K RT-qPCRs for large-scale screening were 248 specific, as these did not yield a positive signal in samples positive for common 249 respiratory tract viruses other than SARS-CoV-2 (Suppl. Tab.2). Based on these 250 results, the RT-qPCRs were implemented into the large-scale screening at TestCenter 251 Denmark, where the sensitivity and specificity were tested in comparison to WGS 252 data (Fig. 4A-C). 253 To validate the RT-qPCR implemented as large-scale screening, results from 9572 254 positive samples were tested both in the RT-qPCR and by WGS over a five-week period from the 7<sup>th</sup> of June 2021 to the 11<sup>th</sup> of July 2021 were compared. This period 255 256 was selected due to the presence of all four key mutations of interest in genomes 257 sequenced as part of this national surveillance strategy. It is also during this period the 258 dominant B.1.1.7 (Alpha) SARS-CoV-2 variant<sup>30</sup> was seen to be replaced by the more 259 transmissible<sup>31</sup> B.1.617.2 (Delta) variant in Denmark. This then allowed for a rigorous 260 test of the RT-qPCR strategy due to the presence and absence of these key mutations 261 amongst these multiple variants (Fig. 1A-B). A daily range of 150 to 671 samples 262 were analysed by multiplex RT-qPCR during this period and results were characterised as either positive (POS) or negative (NEG) for a given key mutation 263 (Fig. 4C). It was observed that there was a small number of inconclusive results 264 265 amongst the E484K RT-qPCRs, as well as a more noticeable number of inconclusive 266 results in the N501Y RT-qPCR which could be attributed to probe manufacturing 267 issues beyond our control - replacement of the probes resulted in a significant reduction in the number of inconclusive results from this reaction (Fig. 4C/lower left 268 panel), Jul 10<sup>th</sup> to Jul 11<sup>th</sup>, 2021). This probe was found to be more sensitive to the 269 270 concentration of the samples, thus samples with high CT values in the initial E-271 Sarbeco based analysis had a tendency to yield inconclusive results. Thus, the N501Y 272 RT-qPCR was more sensitive to minor variations in batch quality. In order to validate 273 all RT-qPCR results and determine the specificity and sensitivity of these 274 primer/probe combinations, WGS consensus genomes from the same samples were 275 used as a reference standard. 276

277 WGS was performed on all positive samples during the study period using the 278 ARCTIC Network's PCR scheme v3 (see Materials and Methods) and the aligned S 279 gene sequences from the resulting consensus genomes were used to validate the 280 results of each of the three RT-qPCR reactions, by comparison of translated codons to 281 RT-qPCR results at each position encoding the four key mutations of interest in this 282 study. Validation was performed on samples where both a valid RT-qPCR result and a 283 consensus genome sequence was obtained, a number which differed for each of the 284 four key mutations for various technical reasons anticipated at this scale (see above). 285 The validation results (Fig. 5) showed good agreement between amino acids 286 translated from WGS and RT-qPCR results for E484K, N501Y and L452R (Fig. 5A-287 C). The determination of concordance proved less straightforward for  $\Delta$ H69/V70 due 288 to the alignment of reads around the deletion prior to consensus generation, resulting

All rights reserved. No reuse allowed without permission.

in a significant discordant fraction between the deletion and negative RT-qPCR
results (Fig. 5D). It was also observed amongst the consensus genomes used in this
validation that amino acid 452 in the spike protein was more mutable than the other
positions which form this set of key mutations, with L, R, M and Q observed at this
position depending on the lineage (Q484 was not observed in genomes during the
selected period but has been recorded in global surveillance data).

295

296 In order to meaningfully compare and describe the relative performance of the RT-297 qPCR strategy from the results of the large-scale screen, as well as to determine the 298 true-positive or true-negative rate of these combinations of primers and probes, the 299 specificity and sensitivity of each primer/probe combination was determined using established methods used to characterise diagnostic testing<sup>32</sup>. Using the validation of 300 the RT-qPCR with WGS as a reference standard, specificities and sensitivities were 301 302 calculated for all primers and probes for the four key mutations, and it was observed 303 that all four RT-qPCRs were highly specific (>99.9%), and three out of four assays 304 were highly sensitive (>99.9%) (Fig. 5 A-D). The sensitivity of the probe for 305 detection of  $\Delta$ H69/V70 was observed to be reduced (79.28%) due to a significant 306 number of deletions in WGS, which were assayed to be negative by RT-qPCR; 307 however, given the challenge of read alignments around genomic regions containing 308 insertions or deletions, this was postulated to be largely due to the determination of 309 the deletion in WGS consensus genomes. In addition to the specificity and sensitivity 310 of the primer/probe combinations, the Positive Predictive Value (PPV) and Negative 311 Predictive Value (NPV) of these combinations was also determined, which indicates 312 the ability of a diagnostic assay or test to accurately detect a condition or in this case, 313 mutation<sup>32</sup>. The determination of PPV and NPV takes into account the specificity and 314 sensitivity of the primer/probe combinations as well as the prevalence of the four key 315 mutations amongst the sequenced SARS-CoV-2 genomes during the study period: 316 It was determined that all four primer/probe combinations had a PPV of at least 97 %, 317 and a NPV of 99.9 % for three out of four of these, with the  $\Delta$ H69/V70 assay having a 318 NPV of 75.43 % (Fig. 5 A-D). From the results of the large-scale screening, it can be 319 seen therefore that the specificity and sensitivity as well as the PPV and NPV all point 320 towards the viability of this RT-qPCR strategy in a large-scale diagnostic setting.

321

322Tab 3 Positive and Negative Predictive Values for all 4 RT-qPCR assays during period of large-<br/>scale screen (7<sup>th</sup> June 2021 to 11<sup>th</sup> July 2021).

Mutation	Prevalence (%) (No. of samples)	PPV (%)	NPV (%)			
ΔH69/V70	61.1 (5010)	99.9	75.4			
N501Y	52.3 (5846)	100.0	99.9			
E484K	0.6 (60)	97.7	100.0			
L452R	35.9 (3441)	99.8	99.9			

324 325 Mutation prevalence estimates were calculated based on consensus sequences from 9572 positive samples (as determined by E-Sarbeco PCR) obtained from this period.

326

327 In summary, we developed a RT-qPCR system for large-scale screening of four key

328 mutations in parallel that is highly specific and sensitive, validated by a comparison of

the qPCR and WGS data from 9572 samples that were tested in parallel.

330

331 **DISCUSSION** 

332

All rights reserved. No reuse allowed without permission.

333 RT-qPCRs platforms for small and large-scale screening can support the detection of 334 mutations of concern present in SARS-CoV-2 variants. This is of special interest for 335 countries lacking an infrastructure for large-scale WGS sequencing, the golden standard for SARS-CoV-2 variant surveillance. Here, a detection system is needed 336 337 that is fast, robust and flexible and, which enables the detection of known diagnostic 338 mutations almost in real-time after sample collection, as we showed in this study. 339 Here, we describe validated and advanced RT-qPCR platforms for small and large-340 scale screening that can simultaneously detect mutations of concern within the S of 341 SARS-CoV-2, with a fast turnaround time for large-scale screening of 12-24h to 342 report to the public health system. In comparison to commercially available systems 343 to detect mutations of concern, the RT-qPCR platforms can be established fast and 344 new mutations can be implemented; an important advantage to follow the course of a 345 pandemic. It is a transparent system, where troubleshooting is possible without 346 depending on the knowledge from a company and it can be adjusted to the existing 847 infrastructure of the laboratory for large-scale screening and data evaluation. 348 Moreover, the RT-qPCR platforms are at low cost of about 10 DKK (2 USD) per 349 reaction, and can therefore be establish in countries without the resources for WGS in 350 large-scale 351 RT-qPCR is a fast, standard method for SARS-CoV-2 detection and has been established at the start of the pandemic in January 2020<sup>29</sup>. The standardised protocol 352 353 for SARS-CoV-2 RT-qPCRs makes it easy to implement into diagnostic laboratories 354 worldwide, where the equipment needed is commonly present. This could be of 355 advantage compared to new methods such as RT-LAMP or CRISPR, which have 356 been described for SARS-CoV-2 detection, delivering faster test results and can be 357 applied without extensive laboratory equipment as RT-qPCRs<sup>33–35</sup>. Currently there are only limited studies on RT-LAMP for commercial point of care<sup>3</sup>. 358 359 Moreover, CRISPR is still in its infancy<sup>36</sup> and has been shown to be less sensitive 360 compared to RT-qPCR<sup>3</sup>. As most diagnostic facilities worldwide do not possess 361 access and knowledge to establish these technologies, opposing to RT-qPCR that is a 362 universal standard method, RT-qPCRs are still the method of choice for most 363 diagnostic laboratories. Based on recent advances in modifications of conjugated-364 probes, RT-qPCRs can be designed to detect mutations within the SARS-CoV-2 365 genome consisting out of a single nucleotide polymorphism (SNP). For small-scale screening the multiplexed RT-qPCR was developed using a Luna 366 367 Probe One-Step RT-qPCR Mix, which offers the possibility to increase the input 368 template concentration, for amplification targets with a low RNA concentration, as it 369 is four times more concentrated. However, this was not an advantage when 370 establishing the multiplexed RT-qPCRs v.1 and v.2, as SARS-CoV-2 RNA 371 concentrations vary among patient samples and can be too high from start leading to 372 artificial signals. In contrast, adjusting the primer and probe concentrations for each 373 mutation resulted in a highly specific and sensitive detection of the corresponding 374 mutation present in the different SARS-CoV-2 variants (Fig. 3J-O, Suppl. Tab. 4). 375 Moreover, by reducing the number of probes in the multiplexed RT-qPCR we could 376 maintain a sensitive system for diagnostic use, by including one probes for each 377 mutation. This was possible by designing and testing combinations of primer and 378 MGB-, LNA- or BHOplus-conjugated probes that yield a specific signal for the 379 mutation and WT sequences, respectively. The best performance for each 380 primer/probe pairs is empirical and should be tested for all possible probe 381 modifications (LNA, MGB and BHQplus), as the result is dependent on the 382 nucleotide sequence of the mutation or WT sequence. So far, only mutations of

All rights reserved. No reuse allowed without permission.

383 concern within the S were included into the multiplexed RT-qPCR platform for small-384 scale screening but running the  $\Delta$ H69/70 RT-qPCR as multiplexed PCR together with 385 the clinical E-sarbeco RT-qPCR did not reduce the sensitivity of the PCR (Fig. 2E). As up to five targets can be included into the multiplex RT-qPCR using the Luna 386 387 Probe One-Step RT-qPCR Mix, additional targets located in other loci of the SARS-388 CoV2 genome than S could be included. We did not test the maximum number of 389 targets that could be included into RT-qPCR platform, as this was out of the scope of 390 this study, but this could be of interest for future studies. 391 Large-scale RT-qPCR screening of mutations present in VOCs required that a number 392 of technical and analytical considerations can be fulfilled: 1) the RT-qPCR must be 393 highly specific and sensitive to minimise or avoid false positives, 2) it should be of 394 sufficient robustness to allow for massive scalability required in a pandemic, 3) it 395 must not interfere with the diagnostic PCR to detect SARS-CoV-2 to reduce the risk 396 of potential PCR contamination 4) it requires liquid handlers in order to be viable 397 from a practicable standpoint and 5) an advanced, automated evaluation system is 398 needed to detect the erroneous results. Here we describe a large-scale RT-qPCR 399 platform that meets the technical and analytical considerations outlined above. The 400 current design is based on sample preparation in a 96-well format and subsequent RT-401 qPCR in 384-format. This allows each sample to be analysed by four separate sets of 402 primers and probes, which enables the analysis of four mutations for up to 92 samples 403 and four controls (one negative and three positive) in parallel in a single run. The 404 system is flexible as the combination of target mutations can be adjusted over time in 405 accordance with current needs. The handling of data calls for automated data 406 processing and variant calling which is due the large amount of data in each run and 407 the complex calling algorithms. Inconclusive results can pose a challenge with regards 408 to variant calling. When one or more of the mutations are inconclusive, it is not 409 always possible to make an unequivocal variant call. In our set-up we have opted to 410 report the detected mutations. In these cases, prominent mutations with putative 411 biological functions in various VOCs were reported, rather than variants of concern 412 and interest. 413 From the large scale-screen it was determined that the RT-qPCR platform described 414 in this study is generally of very high specificity and sensitivity and performs well in 415 terms of its PPV and NPV, indicating its utility in such large-scale diagnostic screens. 416 The period for the large-scale screening and validation was specifically chosen to 417 interrogate the robustness of this system in a pandemic transition period with ongoing 418 lineage replacement; such a period involves the waning of certain variants such as the 419 Alpha (B.1.1.7) and its signature mutations  $\Delta$ H69/V70 and N501Y, along with the 420 rise of a different variant like Delta (B.1.617.2) with a different signature mutation 421 (L452R). In order to have diagnostic value, surveillance mechanisms which track 422 these exclusive signatures, and which do not yield full genomes, must have adequate 423 sensitivity and specificity to be able to adequately distinguish between such signature 424 mutations (this is also aided by the E-Sarbeco PCR result, being the primary 425 diagnostic method used to determine a SARS-CoV-2 infection). In that respect, the 426 sensitivity and specificity of this system is excellent, only falling short in sensitivity in 427 one assay ( $\Delta$ H69/V70) due to distinct technical issues, all of which revolve around the 428 WGS reference standard and not the RT-qPCR itself. Firstly, the challenge of read 429 alignment around genome deletions leads to ambiguous base-calls around these 430 regions. Secondly, in large scale amplicon-based genomic surveillance, dropouts are 431 not a rare occurrence, and a certain degree of N-counts is therefore considered

432 permissible (typically less than 5-10 % of the consensus genome). Tracts of Ns

All rights reserved. No reuse allowed without permission.

433 around this region were observed around the deletion and this was largely responsible 434 for the challenges of identifying a deletion from WGS consensus genomes. However, 435 this was not the case for single SNPs leading to non-synonymous substitutions as seen 436 with N501Y, E484K and L452R. Interesting insights into the specificity and the 437 sensitivity of the RT-qPCR system were also observed in the results around the 438 L452R mutation, given that position L452 in the spike protein exhibited more than a 439 single amino acid change during the pandemic and indeed the timeframe of the large-440 scale screening performed. The validation showed that all samples with L452Q in the 441 spike protein recorded a positive result from the RT-qPCR whereas L452M 442 exclusively recorded negative RT-qPCR results. Given that the codon observed from 443 WGS encoding for Q was cag and the corresponding codon encoding for L at the 444 same position was cgg, this could be considered unsurprising, also given that Q452 445 was not an anticipated mutation and therefore was not considered in the design of the 446 probes. Given that the codon *atg*, which is more distant from *cgg* and which encodes 447 for M at this position, was not detected by the L452R-specific probe, this alludes to 448 the specificity and sensitivity of the RT-qPCR probe at position 452.

449

450 One of the major arms of pandemic control seen in this pandemic revolves around the 451 screening and isolation of SARS-CoV-2 infected individuals in order to limit 452 community spread of infections. The screening and isolation of individuals is 453 therefore time sensitive and requires a rapid turnaround, especially where the control 454 of variants or mutations of concern are a priority. While WGS of positive samples 455 affords the accurate identification of these variants or mutations in order to enable 456 their tracking and therefore control, this entails a longer turnaround time and greater 457 cost in terms of reagents, equipment and expertise. The use of RT-qPCR systems such 458 as the one described in this study allows for rapid identification of mutations of 459 concern, which in turn enables near-real-time tracking of these and correspondingly, 460 rapid decision-making around testing, contact tracing and isolation. This enabled the 461 rapid reaction of the public health system in Denmark to the detection of VOCs, with 462 the added benefit of gaining time to implement its vaccination schedule; being in line 463 with modelling showing that minimising testing delay, had the largest impact on 464 reducing onward transmissions<sup>37</sup>. The flexibility of this system also allows for multiplexing to detect multiple mutations and the incorporation of new primers and 465 probes in response to the dynamics of the SARS-CoV-2 pandemic. In addition, the 466 467 specificity and sensitivity of this system show that it is robust and therefore suited to 468 diagnostic requirements in a pandemic. Taken together, these characteristics make this 469 RT-qPCR system an ideal candidate for laboratories looking to detect mutations of 470 concern in the SARS-CoV-2 pandemic. The current shift in our consideration of the 471 pandemic (towards endemicity) suggests that such monitoring and screening might 472 have to last a considerably longer time, making this system extremely viable in the 473 long-term, and indeed in future outbreaks and pandemics.

474 475

- 476
- 477
- 478
- 479

### 480 Material and Methods

481

#### All rights reserved. No reuse allowed without permission.

#### 482 Ethics

483 Exemption for review by the ethical committee system and informed consent was484 given by the Committee on Biomedical Research Ethics - Capital region in

485 accordance with Danish law on assay development projects.

486

#### 487 Virus isolation

488 SARS-CoV-2 viral isolates representative of VOC (Delta variant B.1.617.2, Alpha 489 variant B.1.1.7 and Beta variant B.1.351 were isolated from PCR-positive throat 490 swabs collected in phosphate buffered saline (PBS) from community testing facilities 491 (Test Center Denmark) and BioBank Denmark, which form part of the Danish 492 national surveillance program<sup>4</sup>. The primary isolation was performed in 24-well culture plates with  $5x10^4$  Vero E6 cells/well seeded the day before. Cells were washed 493 494 once with PBS, and 150-250 µL of swab material and 150-250 µL infection media 495 [Dulbecco's Modified Eagle Medium (DMEM) with 1% Penicillin/Streptomycin] 496 were added to each well. After 1h incubation at 37°C/5% CO<sub>2</sub>, 1 mL/well of 497 propagation media [DMEM with 1% Penicillin/Streptomycin, 5% foetal calf serum] 498 was added, and the cultures were further incubated until cytopathic effect (CPE) was 499 observed. Isolations performed later during the pandemic used additional 1.5 µg/mL 500 Amphotericin B in the propagation media. All cell culture reagents were obtained 501 from Gibco, ThermoFisher Scientific, Waltham, MA, USA. Upon CPE, supernatants were aliquoted and frozen at -80°C. Subsequent passages to expand virus stocks were 502 503 performed in 75 cm<sup>2</sup> flasks seeded with  $1.5 \times 10^6$  Vero E6 the day before. 25  $\mu$ L of 504 primary isolate supernatant was used as inoculum in the presence of 2 mL infection 505 media. After 1h at 37°C/5% CO<sub>2</sub> incubation, flasks were supplemented with 10 mL of 506 propagation media (without Amphotericin) and incubated until CPE was obtained. 507 Supernatants were then clarified by centrifugation for 5 min at 300 x g and stored as 508 single use aliquots at -80°C.

509

### 510 **RT-qPCR validation standards and patient samples**

For determining specificity and sensitivity of the SARS-CoV-2 Variant PCR assays,the following materials were used:

- 513 Diagnostic samples positive for the common respiratory pathogens Human
- 514 Coronavirus 229E, HKU1, NL63 and OC43, Adenovirus and Rhinovirus, was
- 515 obtained as extracted nucleic acids from the human diagnostic Virus PCR laboratory
- 516 at Statens Serum Institute, Denmark, and were all previously confirmed by PCR to be
- 517 positive at high concentration (Ct  $\ll$  30) for respective pathogens.
- 518 Extracted Influenza virus RNA from viruses cultured in Madin Darby Canine Kidney
- 519 (MDCK) cells (A/Christchurch/16/2010(H1N1), pdm09-like virus,
- 520 B/Phuket/3073/2013-like virus, B/Brisbane/60/2008-like virus, were all previously
- 521 confirmed by PCR to be positive at high concentration (Ct <<30) for respective
- 522 pathogens. The influenza reference viruses was provided by the WHO Collaborating
- 523 Centre for Reference and Research on Influenza, The Francis Crick Institute,
- 524 London, United Kingdom. Positive RNA controls for SARS-CoV-2 variants were
- 525 obtained from extracted virus cultures and were diluted in DNase/RNase free water to
- 526 generate CT values between 25-30 in the subsequent RT-qPCR.
- 527 TWIST Synthetic SARS-CoV-2 RNA controls (MT007544.1/Australia/VIC01/2020),
- 528 (MT103907 England/205041766/2020), (MT104043 South African/KRISP-EC-
- 529 K005299/2020) and (MT104044 Japan (IC-0564/2021) were bought from TWIST

All rights reserved. No reuse allowed without permission.

- bioscience and used as PCR standards WT, Alpha (B.1.17), Beta (B.1.351), Gamma
- 531 (P.1), respectively.
- 532 Selected SARS-CoV-2 VOC positive patient samples were obtained from the Danish
- 533 National Biobank.
- 534

### 535 **Positive and Negative controls for the large-scale RT-qPCR platform**

- 536 Positive and negative controls for the large-scale platform were run in parallel with
- 537 selected patient samples throughout extraction and RT-qPCR. DPBS 1x pH 7.2
- 538 (Gibco) was used as negative control. Heat inactivated (56 °C for 45 min.) virus
- 539 cultures, were used as positive control. Three Danish virus isolates were used to cover
- 540 the four key mutations present in the Delta variant B.1.617.2, Alpha variant B.1.1.7
- and Beta variant B.1.351 (SSI-H18).
- 542

### 543 Nucleic acid extraction

- 544 For small scale SARS-CoV-2 patient sample screening, total nucleic acid was
- 545 extracted using a MagNApure96 extraction robot (Roche) with the MagNA Pure 96
- 546 DNA and Viral NA Small Volume kit and the Viral NA Plasma SV protocol (200  $\mu$ L
- 547 input and 100  $\mu$ L elution volume).
- 548 For positive controls, 120 µL of supernatant from SARS-CoV-2 infected cells were
- $\label{eq:mixed_$
- 550 SARS-CoV-2 patient samples. Positive control RNA was stored at -80°C until use.
- 551 For large-scale SARS-CoV-2 patient sample screening, RNA was extracted using a
- Beckman Coulter Biomek i7 robot using the Beckman Coulter RNAdvance Whole
  blood kit (200 µL input and 50 µL elution volume).
- 554

### 555 Primer and probe design

- SARS-CoV-2 variant sequences were retrieved from positive samples identified
  through the national surveillance program in Denmark. Sequences were aligned and
  primer and probes were designed using Geneious Prime 2021.0.
- Two probes were designed for each key mutation: one detecting the wildtype (WT)
- 560 nucleotide sequence, and one detecting the mutation. The probe design was refined to 561 detect the key mutations (L452R, E484K, N501Y,  $\Delta$ 69/V70 deletion) with only one
- 562 probe in the multiplex RT-qPCRs. To ensure stable allelic discrimination analysis,
- 563 probes detecting the mutations with only one nucleotide exchange were either MGB,
- 564 LNA or BHQplus modified, which increases the melting temperature (Tm). The
- 565 calculation of MGB probe Tm was adapted from $^{38}$ .
- 566
- The primers and probes listed in Tab. 2 were synthesized by Biosearch Technologies,
  Denmark, except for the MGB-probes that were synthesized by Eurogentec, Belgium,
  and the Zen-probe, that was synthesized by Integrated DNA Technologies, Belgium.
  All oligos were HPLC-purified.
- 571 572

### Tab.2: Primer and probe sequences.

TargetPrimer/Probe name		Tm	Primer/Probe sequence 5' – 3'	Volum e (µL) <sup>(2)</sup>	Mix ID
SARS-Co	V-2 primary diagnostic a	ssay:			
	E_Sarbeco <sup>31</sup> _F	58.8	ACAGGTACGTTAATAGTTAATAGCGT	0.1	
E-gene	E_Sarbeco_R	61.0	ATATTGCAGCAGTACGCACACA	0.1	
	E_Sarbeco_P1	66.3	FAM-ACACTAGCCATCCTTACTGCGCTTCG- BHQ1	0.05	
Key muta	tions primer and probes (	used in l	arge scale testing:		

All rights reserved. No reuse allowed without permission.
---

(Key muta	ations primers and prob	es used i	n small scale testing, see Mix ID)		
	SARS-CoV- 2 ΔH69/V70 F	58.5	ACATTCAACTCAGGACTTGTTCT	0.1	1, 2, 5
∆H69/V 70	SARS-CoV- 2 ΔH69/V70 R	58.0	TCATTAAATGGTAGGACAGGGTT	0.1	1, 2, 5
	SARS-CoV- 2 ΔH69/V70 P <sup>(1)</sup>	61.2	HEX-TTCCATGCTATCTCTGGGACCA-BHQ2	0.05	1, 2, 5
	SARS-CoV-2 N501Y F	57.7	TGTTACTTTCCTTTACAATCATATGGT	0.1	1, 2, 5, 6
	SARS-CoV-2 N501Y R	58.9	TGCTGGTGCATGTAGAAGTTCA	0.1	1, 2, 5, 6
N501 Y	SARS-CoV-2 501Y_mutant MGB P	64.8	FAM-CCCACTTATGGTGTTGGT-MGB	0.05	2, 5, 6
N501Y S. 50 S. W F F S. F E484K S. 2 F S. S. 5 S. F	SARS-CoV-2 N501 WT MGB P	64.8	Cy5-CCCACTAATGGTGTTGGT-MGB	0.05	2
	SARS-CoV-2_E484K F	58.5	AGGAAGTCTAATCTCAAACCTTTTGA	0.1	3, 5, 6
	SARS-CoV-2_E484K R	60.2	GTCCACAAACAGTTGCTGGTG	0.1	3, 5, 6
E484K	SARS-CoV- 2_484K_mutant MGB FAM P	64.6	FAM-TGGTGTTAAAGGTTTTAAT-MGB	0.05	3
	SARS-CoV- 2_E484K_WT MGB P	63.5	Texas Red-TGGTGTTGAAGGTTTTAA-MGB	0.05	3
	SARS-CoV-2_L452R F	60.5	CAGGCTGCGTTATAGCTTGGA	0.1	4,6
	SARS-CoV-2_L452R R	57.1	CCGGCCTGATAGATTTCAGT	0.1	4,6
L452R	SARS-CoV- 2_452R_mutant BHQ+ P	58.2	HEX-TATAATTACCGGTATAGATTGTT-BHQ1	0.05	4,6
	SARS-CoV- 2_L452_WT BHQ+ P	58.0	Cal Fluor Red 610- TATAATTACC <b>T</b> GTATAGATTGTTTA-BHQ2	0.05	4
Key muta	tion probes used in first v	version o	of N501Y assay, used in large scale testing:	1	
N501Y	SARS-CoV-2 501Y_mutant LNA P	63.2	FAM -CCCAC+T+T+ATGG+TGTTGGT-BHQ1	0.05	1
	SARS-CoV2 N501 WT LNA P	62.6	Quasar 670-CCCAC+T+A+ATGG+TGTTGGT- BHQ2	0.05	1
Key muta		ely in m	ultiplex RT-qPCR in small scale testing:		
ΔH69/V 70	SARS-CoV- 2_∆H69/V70 Zen P	61.2	HEX-TTCCATGCT/ZEN/ATCTCTGGGACCA- IABkFQ	0.05	5
E484K	SARS-CoV- 2_484K_mutant MGB Cy5 P	64.6	Cy5-TGGTGTTAAAGGTTTTAAT-MGB	0.15	5,6

<sup>573</sup> 

577

578

580

#### 581 Mastermix set-up

582 The primers and probes were combined in different master-mixes.

- 583 In master-mix 1-4 (large-scale screening): the mutations were detected using both the
- 584 mutant probe and the wildtype probe for allelic discrimination analysis.
- 585 In master-mix 5 and 6 (small-scale screening), only probes targeting the mutations
- 586 were used, and therefore no allelic discrimination analysis was needed.
- 587
- 588 <u>96-well format PCR conditions used in development phase and small-scale testing</u>
- All PCR assays were developed on a Bio-Rad CFX 96 PCR real-time PCR system.
- 590 Master-mix 1 4 contained 12.5 μL Luna<sup>®</sup> Universal Probe One-step RT-qPCR Kit
- 591 reaction buffer (NEB),  $1.25 \ \mu L \ Luna^{\ensuremath{ extsf{B}}}$  WarmStart RT Enzyme mix, primers and
- 592 probes (100  $\mu$ M, volumes in table 1), DNAse/RNAse free water and 5  $\mu$ L template to

 <sup>574</sup> LNA = Locked Nucleic Acid, a "+" before a nucleotide indicates position of LNA modified base,
 575 MGB = Minor Groove Binder, BHQ+ = BHQplus modified probe. Mastermix ID indicates which
 576 primer and probes were used in the same mastermix. SNP mutations are marked in bold.

<sup>(1)</sup> While it is more common to use a BHQ1 quencher together with HEX, this system works well with a BHQ2 quencher.

<sup>579 (2)</sup> Volumes of oligos added to mastermix are valid for both 96 and 384-well formats.

593 a total volume of 25  $\mu$ L. Cycling conditions: Reverse transcription at 55  $^{0}$ C for 10 594 min., initial denaturation at 95 <sup>o</sup>C for 3 min., followed by 45 cycles of denaturation 595 and annealing/extension at 95 °C for 15 sec. and 58 °C at 30 sec. respectively. 596 Master-mix 5 - 6 contained 5 µL Luna Probe One-Step RT-qPCR 4X Mix with UDG 597 (New England Biolabs Inc (NEB)), primers and probes (100 µM, volumes in Tab. 1), 598 DNAse/RNAse free water and 5µL template to a total volume of 25 µL. Cycling 599 conditions: Initial step at 25°C for 30 sec, reverse transcription at 55 °C for 10 min., initial denaturation at 95 °C for 1 min., followed by 45 cycles of denaturation and 600 annealing/extension at 95°C for 10 sec and 58°C at 60 sec respectively. 601 602 603 Data analysis for the multiplexed RT-qPCRs used in small-scale testing 604 The multiplexed RT-qPCRs contain probes only targeting the mutations,  $\Delta$ H69/V70, 605 501Y, 484K for master-mix 5, and 501Y, 484K, 452R for master-mix 6. Cut-off 606 values were used in the multiplexed RT-qPCRs to secure the detection of only the 607 mutation and not the WT sequence as there was no WT probe in the mix. A sample 608 was considered positive with these criteria: Ct < 38 and RFU (Relative Fluorescence 609 Units) > 500 at Ct = 45. 610 611 384-well format PCR conditions for large-scale testing In large scale testing, the assays run on a Bio-Rad CFX 384 PCR real-time PCR 612 system. The master-mix contained 7.5 µL Luna<sup>®</sup> Universal Probe One-step RT-qPCR 613 614 Kit reaction buffer (New England Biolabs Inc), 0.75 µL Luna<sup>®</sup> WarmStart RT 615 Enzyme mix, primers and probes (100 µM, volumes in table 1), DNAse/RNAse free 616 water and  $5\mu$ L template to a total volume of 15  $\mu$ L. Cycling conditions were the same 617 as for the 96-well format. Each patient sample was analysed in four PCR wells, in 618 four parallel reactions, using master-mix 1 or 2 for detecting  $\Delta$ H69/V70 and N501Y, 619 master-mix 3 for detecting E484K, master-mix 4 for detecting L452R and in the final 620 well the E-Sarbeco assay was used for detection of SARS-CoV-2 wildtype (E-gene). 621 The 4 master-mixes were placed in a quadratic pattern, thus allowing easy transfer 622 from a 96-well plate to a 384-well plate (e.g. A1 in a template plate was pipetted to 623 A1, B1, A2 and B2 of the master mix plate). Master-mix 5 and 6 were not tested in 624 the 384-well format. 625 626 Data analysis using allelic discrimination analysis in large-scale testing 627 PCR curves were evaluated in the Bio-RAD CFX software and Ct values and end 628 RFU were exported in csv files. The files were imported into the laboratory database 629 where all data analysis was performed. For the  $\Delta$ H69/V70 deletion, detection was 630 based on Ct values (deletion detected is Ct = 12-38). For the mutations N501Y, 631 E484K and L452R, detection was based on allelic discrimination where the end RFU 632 values were utilized to determine the presence of a mutation (see Suppl. Tab. 1). A 633 sample was considered positive with these criteria: Ct < 38 and RFU > 200 at Ct = 45. 634 The RFU cut-off value was used in the 384-well PCR-format as a quality control step,

- 635 in case one of the probes in the allelic discrimination pair failed.
- 636
- 637 Whole genome sequencing

638 Whole genome sequences were generated by The Danish COVID-19 Genome

Consortium (DCGC) from PCR-positive samples collected between 6<sup>th</sup> June and 11<sup>th</sup> 639

July 2021. Samples were selected using Ct cut off values between  $30 - 38^{30}$ . The bulk 640

641 of the samples were sequenced using the ARTIC Network tiled PCR scheme V3 via

642 the COVIDseq Assay [Illumina], Artic Network nCoV-2019 sequencing protocol v2

All rights reserved. No reuse allowed without permission.

(dx.doi.org/10.17504/protocols.io.bdp7i5rn [Oxford Nanopore], or a custom DCGC

644 protocol (dx.doi.org/10.17504/protocols.io.bfc3jiyn)[Oxford Nanopore], adapted from 645 the Artic Network protocol. Data pre-processing and consensus genome generation 646 was performed using Illumina-specific (github.com/connor-lab/ncov2019-artic-nf, v. 647 1.3.0) or Oxford Nanopore-specific (github.com/artic-network/fieldbioinformatics, v. 648 1.2.1) consensus pipelines. Consensus genome mutation calling with reference to 649 Wuhan-Hu-1/2019 (Genbank Accession: MN908947) was performed with Nextclade 650 CLI (github.com/nextstrain/nextclade, v. 1.2.0) and lineage designations were 651 performed using pangolin (github.com/cov-lineages/pangolin, v. 3.1.3) with the 652 accompanying pangoLEARN model (github.com/cov-lineages/pangoLEARN, v. 653 1.2.6).

654 655

643

#### 656 <u>RT-qPCR Validation</u>

657

658 Nucleotide sequences corresponding to the Sof consensus genomes derived from 659 WGS were aligned using the MAFFT version 7.480 (*mafft.cbrc.jp*), utilizing the FFT-NS-2 algorithm with a maximum of 1000 iterations<sup>40,41</sup>. Alignments were viewed and 660 processed in Jalview 2.11.1.4 (*jalview.org*,<sup>42</sup>) and codons encoding key mutations 661 662 were extracted, translated and compared to RT-qPCR results. From here, sensitivity, 663 specificity, Positive Predictive Values (PPV) and Negative Predictive Values (NPV) 664 were calculated for each set of primers and probes used in RT-qPCR assays. Positive 665 and Negative Predictive Values were calculated according to the following formulas:

666 667

$$PPV = \frac{Sen*Prev}{(Sen*Prev) + (1-Spec)*(1-Prev)} \quad NPV = \frac{Spec*(1-Prev)}{Spec*(1-Prev) + (1-Sen)*Prev}$$

668

where Sen = sensitivity, Spec = specificity and Prev = prevalence calculated from
WGS consensus genomes. All analyses were performed in Rstudio version 1.4.1717
using R version 4.1.1 and using the packages *tidyverse* (1.3.1), *seqinr* (4.2-8), *lubridate* (1.7.10), ggplot2 (3.3.4), cowplot (1.1.1), zoo (1.8-9) and ggpubr (0.4.0).

674 DATA analysis

675

676 We used standard curves to determine the SARS-CoV-2 detection threshold for each 677 assay and to calculate the viral load in each sample. We used the SARS-CoV-2 678 variant specific TWIST control with a known concentration (copies/µl) and diluted 679 1:10 in a seven-step dilution series. The median Ct-values and the interquartile ranges 680 were calculated based on biological duplicates with technical duplicates. The 681 threshold was based on the intercept of the linear regression line of the standard 682 dilutions. Furthermore, the number of virus particles were estimated based on the 683 logarithmic regression function of each assay's standard dilution series.

684

### 685 Figure legends

686

687Figure 1. Overview of the key mutations located in the spike glycoprotein during688the pandemic and PCR strategies. (A) The spike glycoprotein is located between689the ORF1B and 2a within the SARS-CoV-2 genome. The  $\Delta$ H69/V70 (2 amino acid690deletion) is located in the N-terminal domain (NTD) of the spike glycoprotein and the691L452R, E484K and N501Y mutations are located in the receptor-binding domain

692 (RBD). Sets of four variant specific mutations present in VOC. The Beta (B.1.351) 693 and the Gamma (P.1) have the same key mutations. The y mutations are also present 694 SARS-CoV2 variants that are not variants of concern, but the variants are included

695 into this study for detecting the mutations in patient samples. **B**) Prevalence of spike

- mutations  $\Delta$ H69/V70, N501Y, E484K, L452R amongst SARS-CoV-2 consensus 696
- 697 genomes in Denmark between 7th of June 2021 to the 11th of July 2021 (C) Variant
- 698 composition (by Pangolin nomenclature) harbouring key spike mutations.

699 Figure 2 Schematic overview about the PCR platforms and establishment of the

700 H69/70 RT-qPCR. (A) Multiplexed RT-qPCR v.1 targeting  $\Delta$ H69/70V, E484K- and

- 701 N501Y mutation. The deletion and mutations are detected with one probe respectively
- 702 and the E484K and N501Y mutations are detected by one primer pair resulting in a 703 single amplification product for both mutations. (B) As proof of concept  $\Delta H69/70V$
- 704 was replaced by the L452R mutation of the delta variant (B.1.617.2) in the
- 705 multiplexed RT-qPCR v.2. (C) A HEX-labelled probe detects the  $\Delta$ H69/70 and (D) a
- 706 FAM-labelled probe the WT nucleotide sequence. (E) Dilution row of the TWIST
- 707 control (WT SARS-CoV-2) to detect the limit of detection (F) Detection of the
- 708  $\Delta$ H69/V70 (red bars) or WT sequence (blue bars) in positive SARS-CoV-2 patient
- 709 samples. The positive control (patient sample with the  $\Delta$ H69/V70) is displayed as
- 710 green bar and the negative control as grey bar. (G) Prevalence of top ten SARS-CoV-
- 711 2 variants in Denmark (based on pangolin lineage assignments using WGS-derived
- consensus genomes) from 12<sup>th</sup> Jan 2021 to 8<sup>th</sup> Mar 2021. I) Large scale screening of 712 positive SARS-CoV-2 patient samples in the  $\Delta$ H69/70 RT-qPCR in the period from
- 713  $12^{\text{th}}$  of Jan to the  $8^{\text{th}}$  of March 2021 (**H**) Frequency of  $\Delta$ H69/70V and N501Y 714
- mutations in Denmark from 12<sup>th</sup> Jan to 8<sup>th</sup> Mar 2021, as determined from WGS 715
- 716 consensus genomes obtained in this period. Mutations are relative to Wuhan-Hu-
- 717 1/2019 (Genbank Accession: MN908947). Arrow bars in E and F indicate SEM for
- 718 two technical replicates.

719 Figure 3 Primer and probes performance for the L452R, E484K and N501Y 720 mutations and screening of patient samples positive for SARS-CoV-2 with 721 different mutations of concern present in the multiplexed RT-qPCRs v.1 and v.2 722 A-B) BHQplus-conjugated probes detecting the L452 WT SARS-CoV-2 nucleotide 723 sequence the 452R mutation. C) Dilution row of a patient sample with known whole 724 genome sequence information for the delta variant (B.1.617.2) tested in parallel in the 725 L452R- and E-sarbeco RT-qPCR. D) MGB-conjugated probes detecting the E484 726 WT SARS-CoV-2 nucleotide sequence and the 484K mutation. F) Dilution row of the 727 TWIST control (Gamma P.1) included into the E484K RT-qPCR. G) MGB-728 conjugated probe detecting the N501 WT SARS-CoV-2 nucleotide sequence and the

729 Y501 mutation. I) Dilution row of the TWIST control (Alpha B.1.1.7) included into

730 the N501Y RT-qPCR. J-L) Detection of three key mutations ΔH69/V70, E484K and 731 N501Y in patient samples with known whole genome sequence information identified

- 732 as Alpha (B.1.1.7), Beta (B.1.351) and P.2 variants by the multiplexed RT-qPCR v.1.
- 733 M-O) Detection of three key mutations L452R, E484K and N501Y in patient samples 734 with known whole genome sequence information identified as Alpha (B.1.1.7), Beta
- 735 (B.1.351) and Delta (B.1.617.2) variants by the multiplexed RT-qPCR v.2. Arrow
- 736 bars in C, F and I indicate SEM for two technical replicates.

All rights reserved. No reuse allowed without permission.

Figure 4 Large scale screening of four key mutations. A) Schematic overview of
large-scale screening. B) Primer and probes included into the multiplexed and single
PCR running in the 384-well plate format. C) RT-qPCR results from large-scale
screening for each target mutation: E484K (upper left), L452R (upper right), N501Y
(lower left), ΔH69/70V (lower right) shown as positive (POS, green), negative (NEG,

742 blue) or inconclusive (INK, grey).

Figure 5 Validation of RT-qPCR results from large-scale screening. Concordance 743 744 between RT-qPCR results and WGS results represented as a graphical matrix with 745 each cell represented as a circle showing the number of samples which correspond to 746 a positive (POS, green) or negative (NEG, blue) RT-qPCR result (horizontal axis) and 747 a given amino acid derived from WGS consensus genomes (vertical axis) for E484K 748 (upper left panel), L452R (upper right panel), N501Y (lower left panel),  $\Delta$ H69/70V 749 (lower right panel). Sensitivity and specificity for each RT-qPCR shown at bottom 750 right of each panel.

### 751 Supplementary Figure 1 Detection of the H69/70V deletion by RT-qPCR. A-C)

- 752 Detection of the  $\Delta$ H69/V70 in patient sample with known whole genome sequence
- information identified as Alpha (B.1.1.7), B.1.258 and B.1.298 variants (red bars).
- Positive control (green bar) of sample with known sequence information positive for
- 755 the  $\Delta$ H69/70 and the negative control (grey bar). **D**) Prevalence of all SARS-CoV-2
- variants in Denmark (based on pangolin lineage assignments using WGS-derived
   consensus genomes) from 12<sup>th</sup> Jan 2021 to 8<sup>th</sup> Mar 2021. E) Dilution of the TWIST
- control (WT SARS-CoV-2) and detection of the H69/V70 WT sequence by the
- 759 H69/V70 RT-qPCR or the multiplexed H68/V70 E-sarbeco RT-qPCR. Arrow bars in
- 760 E indicate SEM for two technical replicates.

### 761 Supplementary Figure 2 LNA-modified probes detecting the N501Y mutation.

- 762 **A-B**) LNA probes detecting the 501Y mutation and N501 WT sequence respectively.
- 763 C) Allelic discrimination analysis to differentiate between the 510Y mutation and
- 764 N501WT sequence. **D**) Multiplexed PCR to detect the  $\Delta$ H69/V70 mutation and the
- 765 N501Y mutation.

### 766 Acknowledgements

- We would like to extend our gratitude to Susanne Lopez Rasmussen and Halenur A.
  Bayhan for their assistance and technical support. We would like to acknowledge the
  originating laboratories and WHO Collaborating Centre for Reference and Research
  on Influenza, The Francis Crick Institute, London, United Kingdom for providing
  reference virus material.
- 772

## 773 Author contributions


- 774 Conceptualization: K.S, V.G., E.M., A.A.N., S.M., M.R., R.L., M.W.R., C.P., J.F.,
- A.S.C, C.N. and A.F. Methodology: K.S., V.G., E.M., S.H.N., C.P., M.G.P.J, L.N.
- and DCGC. Investigation/Analysis: K.S., V.G., S.M.K., M.R., J.F. and A.S.C
- 777 Visualization and data curation: K.S, V.G, E.M., A.A.N. and J.F.
- 778 Supervision: A.F., A.S.C and C.P. Writing original draft: K.S. V.G. and A.F. Writing
- reviewing/editing: K.S., V.G., E.M., S.H.N., M.J., A.S.F., L.N., A.A.N., S.M.K.,
- 780 DCGC., S.M., M.R., R.L., M.W.R., C.P., J.F., A.S.C., C.N. and A.F. All authors
- critically revised the manuscript for important intellectual content and gave final
- approval for the submitted version.


783 784 785 786		flict of interest authors declare no competing interests
787	REF	ERENCES
788		
789	1.	Gravagnuolo, A. M. et al. High throughput diagnostics and dynamic risk
790		assessment of SARS-CoV-2 variants of concern. (2021)
791		doi:10.1016/j.ebiom.2021.103540.
792	2.	SARS-CoV-2 variants of concern as of 16 September 2021.
793		https://www.ecdc.europa.eu/en/covid-19/variants-concern.
794	3.	Graham, M. et al. Use of emerging testing technologies and approaches for
795		SARS-CoV-2: review of literature and global experience in an Australian
796		context. <i>Pathology</i> <b>53</b> , 689 (2021).
797	4.	Lyngse, F. P. et al. Association between SARS-CoV-2 Transmissibility, Viral
798		Load, and Age in Households. medRxiv 2021.02.28.21252608 (2021)
799		doi:10.1101/2021.02.28.21252608.
800	5.	Campbell, F. et al. Increased transmissibility and global spread of SARS-CoV-
801		2 variants of concern as at June 2021. Eurosurveillance 26, 1-6 (2021).
802	6.	A, S., J, M., B, T. & C, R. SARS-CoV-2 Delta VOC in Scotland:
803		demographics, risk of hospital admission, and vaccine effectiveness. Lancet
804		(London, England) <b>397</b> , 2461–2462 (2021).
805	7.	Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2.
806		<i>Cell</i> <b>184</b> , 2939-2954.e9 (2021).
807	8.	Funk, T. <i>et al.</i> Characteristics of SARS-CoV-2 variants of concern B.1.1.7,
808		B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.
809	6	<i>Eurosurveillance</i> <b>26</b> , 2100348 (2021).
810	9.	SA, M. <i>et al.</i> Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the
811	10	B.1.351 Variant. N. Engl. J. Med. <b>384</b> , 1885–1898 (2021).
812	10.	Pearson, C. A. Estimates of severity and transmissibility of novel South Africa
813	11	SARS-CoV-2 variant 501Y.V2. 1.
814 015	11.	Cele, S. <i>et al.</i> Escape of SARS-CoV-2 501Y.V2 from neutralization by
815	10	convalescent plasma. <i>Nat. 2021 5937857</i> <b>593</b> , 142–146 (2021).
816 817	12.	Faria, N. R. <i>et al.</i> Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. <i>Science</i> (80 ). <b>372</b> , 6544 (2021).
818	13.	SARS-CoV-2 variants of concern and variants under investigation in England.
819	13. 14.	SARS-Cov-2 variants of concern and variants under investigation in England. Stowe, J. <i>et al.</i> Effectiveness of COVID-19 vaccines against hospital admission
820	14.	with the Delta (B.1.617.2) variant.
821	15.	Welcome - Knowledge Hub.
822	15.	https://khub.net/welcome?p_p_state=normal&p_p_mode=view&saveLastPath=
823		false&_com_liferay_login_web_portlet_LoginPortlet_mvcRenderCommandNa
824		me=%2Flogin%2Flogin&p_p_id=com_liferay_login_web_portlet_LoginPortle
825		t&p_p_lifecycle=0&_com_liferay_login_web_portlet_LoginPortlet_redirect=
826		%2Fdocuments%2F135939561%2F430986542%2FEffectiveness%2Bof%2BC
827		OVID-
828		19%2Bvaccines%2Bagainst%2Bthe%2BB.1.617.2%2Bvariant.pdf%2F204c11
829		a4-e02e-11f2-db19-b3664107ac42.
830	16.	Volz, E. et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England:
831		Insights from linking epidemiological and genetic data.

832		doi:10.1101/2020.12.30.20249034.
833	17.	TN, S. <i>et al.</i> Deep Mutational Scanning of SARS-CoV-2 Receptor Binding
834	17.	
		Domain Reveals Constraints on Folding and ACE2 Binding. <i>Cell</i> <b>182</b> , 1295-
835	10	1310.e20 (2020).
836	18.	Zhou, R. <i>et al.</i> Viral dynamics in asymptomatic patients with COVID-19. <i>Int.</i>
837	10	J. Infect. Dis. <b>96</b> , 288–290 (2020).
838	19.	Y, W. <i>et al.</i> Escape from neutralizing antibodies by SARS-CoV-2 spike protein
839	• •	variants. <i>Elife</i> <b>9</b> , 1 (2020).
840	20.	TN, S. et al. Prospective mapping of viral mutations that escape antibodies
841		used to treat COVID-19. <i>Science</i> <b>371</b> , 850–854 (2021).
842	21.	Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune
843		escape. doi:10.1038/s41579-021-00573-0.
844	22.	Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate
845		monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477-
846		488.e4 (2021).
847	23.	AJ, G. et al. Comprehensive mapping of mutations in the SARS-CoV-2
848		receptor-binding domain that affect recognition by polyclonal human plasma
849		antibodies. Cell Host Microbe 29, 463-476.e6 (2021).
850	24.	Boklund, A. et al. Monitoring of SARS-CoV-2 infection in mustelids. EFSA J.
851		<b>19</b> , (2021).
852	25.	Hammer, A. S. et al. SARS-CoV-2 transmission between mink (neovison
853		vison) and Humans, Denmark. Emerg. Infect. Dis. 27, 547-551 (2021).
854	26.	Lassaunière, R. et al. In vitro Characterization of Fitness and Convalescent
855		Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink
856		at Danish Farms. <i>Front. Microbiol.</i> <b>0</b> , 1679 (2021).
857	27.	Özkan, E. <i>et al.</i> High-throughput Mutational Surveillance of the SARS-CoV-2
858	_/.	Spike Gene. <i>medRxiv</i> 2021.07.22.21259587 (2021)
859		doi:10.1101/2021.07.22.21259587.
860	28.	Jørgensen, T. S. <i>et al.</i> A rapid, cost efficient and simple method to identify
861	20.	current SARS-CoV-2 variants of concern by Sanger sequencing part of the
862		spike protein gene. <i>medRxiv</i> 2021.03.27.21252266 (2021)
863		doi:10.1101/2021.03.27.21252266.
864	29.	VM, C. <i>et al.</i> Detection of 2019 novel coronavirus (2019-nCoV) by real-time
865	2).	RT-PCR. Euro Surveill. 25, (2020).
866	30.	Michaelsen, T. Y. <i>et al.</i> Introduction and transmission of SARS-CoV-2 B.1.1.7
867	50.	in Denmark. <i>medRxiv</i> 2021.06.04.21258333 (2021)
868	21	doi:10.1101/2021.06.04.21258333.
869	31.	Li, B. <i>et al.</i> Viral infection and transmission in a large, well-traced outbreak
870		caused by the SARS-CoV-2 Delta variant. <i>medRxiv</i> 2021.07.07.21260122
871	22	(2021) doi:10.1101/2021.07.07.21260122.
872	32.	Trevethan, R. Sensitivity, Specificity, and Predictive Values: Foundations,
873		Pliabilities, and Pitfalls in Research and Practice. <i>Front. Public Heal.</i> <b>0</b> , 307
874	22	(2017).
875	33.	Huang, W. E. <i>et al.</i> RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-
876		2. <i>Microb. Biotechnol.</i> <b>13</b> , 950–961 (2020).
877	34.	Lim, B. <i>et al.</i> Clinical validation of optimised RT-LAMP for the diagnosis of
878	<b>a</b> =	SARS-CoV-2 infection. Sci. Reports 2021 111 11, 1–11 (2021).
879	35.	Broughton, J. P. et al. CRISPR–Cas12-based detection of SARS-CoV-2. Nat.
880		Biotechnol. 2020 387 <b>38</b> , 870–874 (2020).
881	36.	Mustafa, M. I. & Makhawi, A. M. Sherlock and detectr: CRISPR-cas systems

882 883		as potential rapid diagnostic tools for emerging infectious diseases. J. Clin. <i>Microbiol.</i> <b>59</b> , (2021).
884	37.	Kretzschmar, M. E. <i>et al.</i> Impact of delays on effectiveness of contact tracing
885		strategies for COVID-19: a modelling study. Lancet. Public Heal. 5, e452
886		(2020).
887	38.	Afonina, I. et al. Efficient priming of PCR with short oligonucleotides
888		conjugated to a minor groove binder. Nucleic Acids Res. 25, 2657 (1997).
889	39.	Tyson, J. R. et al. Improvements to the ARTIC multiplex PCR method for
890		SARS-CoV-2 genome sequencing using nanopore. <i>bioRxiv</i> <b>3</b> , 1 (2020).
891	40.	Katoh, K. & Standley, D. M. MAFFT Multiple Sequence Alignment Software
892		Version 7: Improvements in Performance and Usability. Mol. Biol. Evol. 30,
893		772 (2013).
894	41.	K, K., K, M., K, K. & T, M. MAFFT: a novel method for rapid multiple
895		sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30,
896		3059–3066 (2002).
897	42.	Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M. & Barton, G. J.
898		Jalview Version 2—a multiple sequence alignment editor and analysis
899		workbench. Bioinformatics 25, 1189–1191 (2009).
900		
901		

## Figure 1









Figure 3 medRxiv preprint doi: https://doi.org/10.1101/2021.10.25.21265484; this version posted October 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


All rights reserved. No reuse allowed without permission.

### Figure 4

#### Large scale screening - single and multiplexed RT-qPCRs




## Figure 5




All rights reserved. No reuse allowed without permission.

### Supplementary Fig.1




D



B.1.177.21	B.1.36.25	B.1.1.318	D.5
B.1.177.12	AD.1	B.1.177.50	B.1.1.221
B.1.160	B.1.177.82	B.1.177.73	B.1.1.222
B.1.177.86	B.1.160.24	B.1.36.33	B.1.1.241
B.1.221.3	B.1.177.77	B.1.1.348	B.1.1.280
B.1.258	B.1.258.16	B.1.177.75	B.1.1.298
B.1.177.60	B.1.258.22	B.1.534	B.1.1.413
B.1.177.35	B.1.177.41	A.21	B.1.1.420
B.1.221	B.1.351	A.23.1	B.1.1.434
B.1.525	B.1.36.31	A.28	B.1.1.47
B.1.177	C.35	B.1.1.1	B.1.1.521
B.1.258.11	C.36	B.1.1.374	B.1.143
B.1.177.76	B.1.429	B.1.160.17	B.1.177.4
B.1.177.42	U.2	B.1.236	B.1.177.4
B.1.1.433	B.1.177.39	B.1.398	B.1.177.5
B.1.1.70	B.1.258.17	B.1.536	B.1.177.6
B.1.1	B.1.1.351	P.1	B.1.222
B.1	P.2	В	B.1.234
B.1.214.4	B.1.177.46	B.1.1.216	B.1.243
B.1.177.81	B.1.1.317	B.1.1.302	B.1.258.19
B.1.177.24	B.1.1.397	B.1.1.354	B.1.264
B.1.160.8	B.1.1.153	B.1.1.428	B.1.36.10
AB.1	B.1.177.79	B.1.1.429	B.1.36.22
B.1.480	B.1.1.219	B.1.160.32	B.1.36.8
B.1.36	B.1.2	B.1.177.9	B.1.466.1
B.1.1.377	B.1.469	B.1.36.1	B.1.471
B.1.523	B.1.1.277	B.1.362.2	C.16
B.1.177.80	B.1.131	B.1.427	R.1
B.1.1.170	B.1.258.9	B.1.575	Z.1

Е



- 1250 copies/µl
- 1250 copies/µl multiplex
- 125 copies/µl
- 125 copies/µl multiplex
- 12,5 copies/µl
- 12,5 copies/µl multiplex
- 1,25 copies/µl
- 1,25 copies/µl multiplex
- N/D
- N/D

Supplementary Fig.2

